Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Covey

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer Research|November 1, 1986
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cellsJ M Covey, M D'Incalci, E J Tilchen, et al.
Cancer Research|February 1, 1988
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cellsY Pommier, D Kerrigan, J M Covey, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 1994
Liquid chromatographic analysis, stability and protein binding studies of the anti-HIV agent benzoic acid, 2-chloro-5[[(1-methylethoxy)thioxomethyl]amino]-,1-methylethyl esterA A Nomeir, M F McComish, A L Mongan, et al.
Cancer Research|April 15, 1987
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cellsJ Markovits, Y Pommier, D Kerrigan, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 3, 1998
Liquid chromatographic analysis in mouse, dog and human plasma; stability, absorption, metabolism and pharmacokinetics of the anti-HIV agent 2-chloro-5-(2-methyl-5,6-dihydro-1,4-oxathiin-3-yl carboxamido) isopropylbenzoate (NSC 615985, UC84)A A Nomeir, M F McComish, N F Ferrala, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2001
Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazolesC J Koch, S M Hahn, K Rockwell, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 ratsK P Stecklair, D R Hamburger, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1M J Egorin, E G Zuhowski, D M Rosen, et al.
Journal of Experimental Therapeutics & Oncology|May 1, 1996
Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblastsJ J Barchi, D A Cooney, G S Ahluwalia, et al.
Journal of Medicinal Chemistry|June 19, 1998
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal applicationO M Howard, J J Oppenheim, M G Hollingshead, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer Research|November 1, 1986
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cellsJ M Covey, M D'Incalci, E J Tilchen, et al.
Cancer Research|February 1, 1988
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cellsY Pommier, D Kerrigan, J M Covey, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 1994
Liquid chromatographic analysis, stability and protein binding studies of the anti-HIV agent benzoic acid, 2-chloro-5[[(1-methylethoxy)thioxomethyl]amino]-,1-methylethyl esterA A Nomeir, M F McComish, A L Mongan, et al.
Cancer Research|April 15, 1987
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cellsJ Markovits, Y Pommier, D Kerrigan, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 3, 1998
Liquid chromatographic analysis in mouse, dog and human plasma; stability, absorption, metabolism and pharmacokinetics of the anti-HIV agent 2-chloro-5-(2-methyl-5,6-dihydro-1,4-oxathiin-3-yl carboxamido) isopropylbenzoate (NSC 615985, UC84)A A Nomeir, M F McComish, N F Ferrala, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2001
Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazolesC J Koch, S M Hahn, K Rockwell, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 ratsK P Stecklair, D R Hamburger, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1M J Egorin, E G Zuhowski, D M Rosen, et al.
Journal of Experimental Therapeutics & Oncology|May 1, 1996
Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblastsJ J Barchi, D A Cooney, G S Ahluwalia, et al.
Journal of Medicinal Chemistry|June 19, 1998
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal applicationO M Howard, J J Oppenheim, M G Hollingshead, et al.
Pageof 4